<DOC>
	<DOCNO>NCT01378156</DOCNO>
	<brief_summary>GV-TH-01 open label Phase 1 study 9 HIV-1 infected adult suppress viremia start anti-retroviral therapy ( ART ) within 18 month negative HIV antibody test . This study 3 phase . The first phase vaccination phase , patient vaccinate pGA2/JS7 ( JS7 ) DNA MVA62B vaccines prime/boost regimen . The second phase study treatment interruption phase , whereby ART interrupt 12 week period approximately 8 week follow last vaccination . The third phase occur 12 week treatment interruption phase call treatment reinstitution phase , subject reinstitute ART follow additional 24 week . The primary objective evaluate safety vaccine three phase study . A secondary objective evaluate immunogenicity vaccine vaccination phase study .</brief_summary>
	<brief_title>A Safety Immunogenicity Study Plasmid DNA Prime MVA Boost Vaccine HIV-1 Infected Adults ART</brief_title>
	<detailed_description>GV-TH-01 open label Phase 1 study 9 HIV-1 infected adult suppress viremia start anti-retroviral therapy ( ART ) within 18 month negative HIV antibody test . This study 3 phase . The first phase vaccination phase , patient vaccinate pGA2/JS7 ( JS7 ) DNA MVA62B vaccines prime/boost regimen week 1 9 ( JS7 DNA vaccine ) week 17 25 ( MVA62B ) . Both vaccine express Gag , Pol , Env . The second phase study treatment interruption phase , whereby ART interrupt 12 week period approximately 8 week follow last vaccination . The third phase occur 12 week treatment interruption phase call treatment reinstitution phase , subject reinstitute ART follow additional 24 week . The primary objective evaluate safety vaccine three phase study . A secondary objective evaluate immunogenicity vaccine vaccination phase study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 1850 yr . ART start within 18 mo . last documented negative HIV Ab test , within 13 mo . last negative detuned HIV1 Ab assay , within 18 mo . evolution Western blot indeterminate positive presence positive Ab test No change ART treatment within 4 wks . study entry Documentation level plasma HIV1 RNA CD4+ count prior ART On stable suppressive ART [ HIV1 RNA &lt; 50 copies/mL ( PCR ) &lt; 75 copies/mL ( bDNA ) least 6 mo . prior start vaccination ] No history virologic failure CD4+ &gt; 500 cells/µL Nadir CD4+ &gt; 350 cells/µL unless measure set acute infection Laboratory value : Hemoglobin ≥ 10g/dL ( male ) 9g/dL ( woman ) ANC &gt; 1000 cells/µL ALT , AST ≤ 2.5 ULN Total bilirubin &lt; 1.5 x ULN ( ≤ 5 x ULN atazanavir ) Fasting glucose ≤ 125 mg/dL Serum creatine &lt; 1.5 x ULN Creatinine clearance ≥ 60 mL/min ( CockcroftGault ) Serum creatine phosphokinase ( CPK ) ≤ 1.5 x ULN UA negative hemoglobin glucose great 1+ protein Any abnormality must assess investigator clinically significant ECG without evidence current past MI , ischemic heart disease Willing provide sign informed consent Females : negative serum urine βHCG pregnancy test screen Female subject reproductive potential engage sexual activity could lead pregnancy must agree avoid pregnancy agree consistently use contraception least 21 day prior first vaccination last protocol visit . Male subject participate study must agree attempt impregnate female , participate sperm donation program Males engage sexual activity could lead pregnancy must use condom date receipt first study vaccine last protocol visit Agreement use condom protection HIV1 transmission throughout study Participants must willing comply study requirement expect available duration study Participants must willing temporarily discontinue antiretroviral therapy 12 wks . postvaccinations Known infection HIV1 subtype Clade B Chemotherapy active malignancy past 12 mo . Prior vaccination HIV1 vaccine Prior vaccination smallpox within last 15 yr . History known cardiac disease History myositis Diagnosis HIVassociated nephropathy Evidence active HBV HCV infection Framingham Global Risk Assessment Score consistent high shortterm ( 10 yr. ) cardiac risk Receipt immunomodulatory agent , systemic corticosteroid ( include nonprescription street steroid ) , gamma globulin , investigational agent ( H1N1 influenza vaccine ) within 6 mo . screen Any immunization within 1 mo . screen within 2 wks . inoculation study Creatine supplement within 14 day baseline unwillingness discontinue use throughout trial Changes ART regimen prior entry due virologic failure ( include toxicity ) Pregnancy breastfeed Any clinically significant disease ( HIV1 infection ) clinically significant finding screen medical history physical examination , investigator 's opinion , would compromise participant safety Active alcohol substance abuse Allergy chicken egg derive product Contraindication intramuscular injection Unwilling forego vigorous exercise 3 day prior vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Therapy HIV Infection</keyword>
	<keyword>Suppressive ART failure</keyword>
	<keyword>Treatment interruption</keyword>
</DOC>